

IFW


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. MPI-0003	
In Re Application Of: Amy F. T. Arnsten, et al.					
Application No. 10/672,626	Filing Date 09/26/2003	Examiner George W. Mitchell	Examiner No. 23413	Group Art Unit 1614	Confirmation No. 8080
Title: CHELERYTHRINE, ANALOGS THEREOF AND THEIR USE IN THE TREATMENT OF BIPOLAR DISORDER AND OTHER COGNITIVE DISORDERS					
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
37 CFR 1.97(b)					
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
37 CFR 1.97(c)					
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:					
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);					
OR					
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).					

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
MPI-0003

In Re Application: Amy F. T. Arnsten, et al.

MAR 07 2005



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/672,626	09/26/2003	George W. Mitchell	23413	1614	8080

Title: **CHELERYTHRINE, ANALOGS THEREOF AND THEIR USE IN THE TREATMENT OF BIPOLAR DISORDER AND OTHER COGNITIVE DISORDERS**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 06-1130 as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

March 4, 2005

(Date)

Laura J. Nolan
Signature of Person Mailing Correspondence

Laura J. Nolan

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**

Leslie Anne Horvath
Signature

Dated: March 4, 2005

Leslie-Anne Horvath

Reg. No. 44,778

(860) 286-2929

CC:

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Amy F. T. Arnsten, et al.

Docket No.

MPI-0003

Application No.

10/672,626

Filing Date

09/26/2003

Examiner

George W. Mitchell


Customer No.

23413

Group Art Unit

1614

Invention: CHELERYTHRINE, ANALOGS THEREOF AND THEIR USE IN THE TREATMENT OF BIPOLAR DISORDER AND OTHER COGNITIVE DISORDERS




I hereby certify that this Trans. of IDS (2 pgs), IDS (1 pg), PTO-A820 (4 pgs), Cited Art (29 refs), pasted
(Identify type of correspondence)

is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on
March 4, 2005
(Date)

Laura J. Nolan

(Typed or Printed Name of Person Mailing Correspondence)


(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.



MPI-0003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Amy F. T. Arnsten, et al.)
Serial No.: 10/672,626) Group Art Unit: 1614
Filed: September 26, 2003) Before the Examiner:
George W. Mitchell)
For: CHELERYTHRINE, ANALOGS THEREOF)
AND THEIR USE IN THE TREATMENT)
OF BIPOLAR DISORDER AND OTHER)
COGNITIVE DISORDERS)

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98


Sir:

In compliance with the duty to disclose, submitted herewith is form PTO-A820 (PTO-1449) listing publication(s) of which those designated by 37 CFR § 1.56 are aware. Copies of the non-United States patents or published applications are enclosed.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made, or an admission that the information cited is, or is considered to be, material to patentability.

Respectfully submitted,

CANTOR COLBURN LLP

By: 
Leslie-Anne Horvath
Reg. No. 44,778

Date: March 4, 2005
Customer No.: 23413
Telephone: (860) 286-2929

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

MPI-0003

Application Number

10/672,626

Applicant(s)

Amy F.T. Arnsten, et al.

Filing Date

09/26/2003

Group Art Unit

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

	1	Arnsten, A.F.T., et al. "Dopamine D1 Receptor Mechanisms In The Cognitive Performance Of Young Adult And Aged Monkeys", Psychopharmacology (Berl), (1994) 116(2):143-151
	2	Arnsten, A.F.T., et al. "The Alpha-1 Adrenergic Agonist, Cirazoline, Impairs Spatial Working Memory Performance In Aged Monkeys", Pharmacology Biochemistry and Behavior, (1997) 58(1): 55-59

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) MPI-0003		Application Number 10/672,626	
		Applicant(s) Amy F.T. Arnsten, et al.			
		Filing Date 09/26/2003		Group Art Unit 1614	
*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>				
3	Arnsten, Amy F.T., et al. "Noise Stress Impairs Prefrontal Cortical Cognitive Function in Monkeys", Arch Gen Psychiatry, (1998) 55(4):362-368				
4	Arnsten, Amy F. T. "The Biology of Being Frazzled", Science,(1998) 280(5370):1711-1712				
5	Arnsten, Amy F.T., et al. "Alpha-1 Noradrenergic Receptor Stimulation Impairs Prefrontal Cortical Cognitive Function", Society of Biological Psychiatry (1999) 45(1):26-31				
6	Arnsten, Amy F.T. "Stress Impairs Prefrontal Cortical Function In Rats And Monkeys: Role Of Dopamine D1 And Norepinephrine Alpha-1 Receptor Mechanisms" Progress In Brain Research ,(2000) Chapter 12, 126:183-192				
7	Arnsten, Amy F. T., et al. "The Selective Dopamine D4 Receptor Antagonist, PNU-101387G, Prevents Stress-Induced Cognitive Deficits In Monkeys" Neuropsychopharmacology, American College of Neuropsychopharmacology, (2000) 23(4):405-410				
8	Avery, Robert A., et al. "The Alpha-2A-Adrenoceptor Agonist, Guanfacine, Increases Regional Cerebral Blood Flow In Dorsolateral Prefrontal Cortex Of Monkeys Performing a Spatial Working Memory Task", Neuropsychopharmacology (2000) American College of Neuropsychopharmacology, 23(4):240-249				
9	Bedchuk, Joseph M. et al. "A Preliminary Investigation of a Protein Kinase C Inhibitor in the Treatment of Acute Mania", Arch Gen Psychiatry, (2000) 57(1):95-97				
10	Birnbaum, Shari, et al. "A Role for Norepinephrine in Stress-Induced Cognitive Deficits: alpha-1-Adrenoceptor Mediation in the Prefrontal Cortex", Society of Biological Psychiatry (1999) 46(9):1266-1274				
11	Blumberg, M.D., Hilary P., et al. "Rostral and Orbital Prefrontal Cortex Dysfunction In The Manic State Of Bipolar Disorder", Am J Psychiatry (1999) 156(12):1986-1988				
12	Casey, Ph.D., B.J., et al. "Implication Of Right Frontostriatal Circuitry In Response Inhibition And Attention-Deficit/Hyperactivity Disorder", J. Am. Acad. Child Adolesc. Psychiatry (1997) 36(3):374-383				
13	Drevets, Wayne C., et al. "Subgenual Prefrontal Cortex Abnormalities In Mood Disorders", Nature, (1997) 386(6627):824-827				
14	Duman, Ronald S., et al. "Signal Transduction Pathways for Catecholamine Receptors" Psychopharmacology: The Fourth Generation of Progress", Raven Press, Ltd, 1995 pp. 303-320				
EXAMINER		DATE CONSIDERED			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>					

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) MPI-0003		Application Number 10/672,626	
		Applicant(s) Amy F.T. Arnsten, et al.			
		Filing Date 09/26/2003		Group Art Unit 1614	

*EXAMINER INITIAL	OTHER DOCUMENTS	(Including Author, Title, Date, Pertinent Pages, Etc.)
15		Franowicz, J. Steere, et al. "The Alpha-2a Noradrenergic Agonist, Guanfacine, Improves Delayed Response Performance In Young Adult Rhesus Monkeys", Psychopharmacology (1998) 136:8-14
16		Glass, David C., et al. "Behavioral Aftereffects Of Unpredictable And Uncontrollable Aversive Events", American Scientist, (1972) 60(4):457-465
17		Goldman-Rakic, P.S. "The Prefrontal Landscape: Implications of Functional Architecture For Understanding Human Mentation And The Central Executive", Phil. Trans. R. Soc. Lond. B (1996) 351(1346):1445-1453
18		Goldman-Rakic, Patricia S. "Regional And Cellular Fractionation Of Working Memory", Proc. Natl. Acad. Sci. USA (1996) 93(24):13473-13480
19		Hammen, Ph.D., Constance, et al. "Stress Reactivity In Bipolar Patients And Its Relation To Prior History Of Disorder", Am J Psychiatry (1997) 154(6):856-857
20		Hartley, L.R., et al. "Effect Of Noise On The Stroop Test", Journal of Experimental Psychology,(1974) 102(1):62-66
21		Manji, Hussein K., et al. "Protein Kinase C Signaling In The Brain: Molecular Transduction Of Mood Stabilization In The Treatment Of Manic-Depressive Illness", Society of Biological Psychiatry (1999), 46(10):1328-1351
22		Mao, Zheng-Mei, et al. "Local Infusion Of An Alpha-1 Adrenergic Agonist Into The Prefrontal Cortex Impairs Spatial Working Memory Performance In Monkeys", Society of Biological Psychiatry (1999) 46(9):1259-1265
23		Murphy, Beth L., et al. "Dopamine And Spatial Working Memory In Rats And Monkeys: Pharmacological Reversal of Stress-Induced Impairment", The Journal of Neuroscienc e (1996), 16(23):7768-7775
24		Robbins, T.W. "Dissociating Executive Functions Of The Prefrontal Cortex", Phil. Trans. R. Soc. Lond. B (1996) 351(1346):463-471
25		Southwick, Steven M., et al. "Role Of Norepinephrine In The Pathophysiology And Treatment Of Posttraumatic Stress Disorder", Society of Biological Psychiatry (1999) 46:1192-1204
26		Sun, Grace Y., et al. "Lithium Effects On Inositol Phospholipids And Inositol Phosphates: Evaluation Of An In Vivo Model For Assessing Polyphosphoinositide Turnover In Brain", Journal of Neurochemistry,(1992) 58(1): 290-297
EXAMINER		DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

